表柔比星联合紫杉醇新辅助化疗法治疗三阴性乳腺癌的效果分析

王永杰

（澄合矿务局中心医院内一科，陕西 渭南，715200）

浏览次数：120次 下载次数：532次

摘要：

目的 探讨表柔比星联合紫杉醇的新辅助化疗法治疗三阴性乳腺癌的临床疗效。方法 选取我院治疗的110例三阴性乳腺癌患者为研究对象，按照不同的治疗方法分为对照组与治疗组，每组55 例。对照组患者采取表柔比星治疗，治疗组采用表柔比星联合紫杉醇的新辅助化疗法治疗，对比两组患者的治疗效果、不良反应和Kamofsky评分。结果 治疗组患者的总有效率显著高于对照组（P<0.05）；两组不良反应发生率比较，无显著差异（P>0.05）；治疗组患者的Kamofsky评分显著高于对照 组（P<0.05）。结论 表柔比星联合紫杉醇的新辅助化疗法治疗三阴性乳腺癌的疗效较好，值得进一步研究。

关键词：三阴性乳腺癌；表柔比星；紫杉醇；新辅助化疗

中图分类号：R737.9文献标志码：A文章编号：2096-1413(2017)18-0027-02

Effect analysis of epirubicin combined with paclitaxel neoadjuvant chemotherapy in the treatment of triple negative breast cancer
WANG Yong-jie
(Department of No.1 Internal Medicine, Chenghe Mining Bureau Central Hospital, Weinan 715200, China)

ABSTRACT: Objective To investigate the clinical efficacy of epirubic combined with paclitaxel neoadjuvant chemotherapy in the treatment of triple negative breast cancer. Methods A total of 110 patients with triple negative breast cancer admitted in our hospital were selected as the research objects. All the patients were divided into control group and treatment group according to different treatment methods, with 55 cases in each group. The control group was treated with epirubicin, while the treatment group was treated with epirubicin combined with paclitaxel neoadjuvant chemotherapy. The clinical effects, adverse reactions and Kamofsky scores of the two groups were compared. Results The total effective rate of treatment group was significantly higher than that of the control group (P<0.05). There was no significant difference on the incidence rate of adverse reactions between the two groups (P>0.05). The Kamofsky score of the treatment group was higher than that of the control group (P<0.05). Conclusion Epirubicin combined with paclitaxel neoadjuvant chemotherapy in the treatment of triple negative breast cancer has significant clinical effect, which deserves further research.
KEYWORDS: triple negative breast cancer; epirubicin; paclitaxel; neoadjuvant chemotherapy

参考文献：
[1] 王萍丽,栗红利.乳腺癌术后患者功能锻炼中护理干预的效果观察 [J].陕西医学杂志,2014,43(6):767-768.
[2] 李林,朱明智,王芳,等.多西他赛联合卡铂方案在三阴性乳腺癌新辅助化疗中的疗效分析[J].肿瘤基础与临床,2016,29(4):314-315.
[3] SHIMADA H,UEDA S,SAEKI T,et al.Neoadjuvant triweekly nanoparticle albumin -bound paclitaxel followed by epirubicin and cyclophosphamide for stage II/III HER2-negative breast cancer: evaluation of ef原 ficacy and safety[J].Jpn J Clin Oncol,2015,45(7):642-649.
[4] 卢转飞,林琪,陈明聪,等.多西他赛、表柔比星及环磷酰胺联合化疗对乳腺癌新辅助化疗患者疗效观察[J].药物流行病学杂志,2015,24(3):136-138.
[5] 唐武平.表柔比星联合紫杉醇的新辅助化疗方法治疗三阴性乳腺癌的效果[J].中外医疗,2015,23(31):117-118.
[6] 刘亮,张森.多西紫杉醇联合表柔比星新辅助化疗治疗乳腺癌的疗效分析[J].中国肿瘤临床与康复,2014,21(6):703-705.
[7] 马溪近,陈德滇,张季.乳腺癌新辅助化疗的若干问题[J].中国社区医师:医学专业,2013,15(4):49-50.
[8] 赵华锋,许菊萍,王辉,等.AC方案与FAC方案新辅助化疗治疗乳腺癌的临床疗效比较[J].肿瘤药学,2016,6(4):303-305.
[9] 张莉.紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌的疗效[J].中外医学研究,2014,12(25):4-6.
[10] 李淑青,陈亚萍.卵巢癌对顺铂和紫杉醇耐药的分子机制[J].国际 妇产科学杂志,2016,43(2):145-150.
[11] 韩忠良.表柔比星联合紫杉醇的新辅助化疗方法治疗三阴性乳腺癌的效果[J].世界最新医学信息文摘:连续型电子期刊,2015,15(30):65,68.
[12] 倪晨,李婷,吴振华,等.三阴性乳腺癌化疗进展[J].中国癌症杂志,2014,24(4):316-320.